Eve Health Group Ltd (ASX:EVE) has increased the size of its recent capital raising to about $1.3 million after securing a $400,000 commitment from a cornerstone investor, strengthening support for its pharmaceutical reformulation strategy.
The additional investment was made on the same terms as the placement announced earlier in March, signalling confidence in the company’s development pipeline and commercial approach.
“We are pleased to welcome a cornerstone investor with experience in pharmaceutical development and commercialisation as part of this placement,” Ben Rohr, chief operating officer of EVE Health Group, said.
“The additional investment strengthens the company’s funding position and reflects growing support for EVE’s strategy of developing improved delivery formats for established pharmaceutical compounds targeting large global markets.”
The cornerstone investor brings experience across pharmaceutical development, regulatory pathways and global commercialisation, providing strategic backing beyond capital.
EVE said the investment reflects growing external support for its model of reformulating established pharmaceutical compounds approaching patent expiry using proprietary delivery and solubilisation technologies.
Funding to advance pipeline and technology
The money raised will be directed toward advancing EVE’s portfolio of reformulated pharmaceutical candidates targeting large global markets, particularly in sexual health and cardiovascular therapies.
Funds will also support further development of the company’s drug delivery and solubilisation technologies, as well as intellectual property and regulatory activities required to progress products toward commercialisation.
EVE’s strategy centres on improving existing medicines with well-established safety profiles by enhancing bioavailability, onset of action and patient convenience, while generating new intellectual property.
Targeting large global markets
EVE is building a pipeline of reformulated drug candidates aimed at therapeutic markets estimated to exceed US$30 billion annually, leveraging opportunities where patents on existing drugs are nearing expiry.
The company intends to commercialise these products through licensing or supply partnerships with pharmaceutical companies that have established manufacturing, regulatory and distribution capabilities.
The placement was priced at $0.02 per share, with investors receiving two free attaching unlisted options exercisable at $0.04 and expiring in two years. Settlement is expected around March 20, 2026.
All aboutt EVE
EVE Health Group is an Australian life sciences company developing and commercialising pharmaceutical products in growth therapy markets. Its key assets include Dyspro®, a cannabinoid-based pastille aimed at dysmenorrhoea and endometriosis, and LibboTM, an oral dissolving film for erectile dysfunction designed for faster onset and easier use. Both products are built on EVE’s proprietary formulation and delivery technologies, which are intended to improve bioavailability and patient outcomes while supporting near-term commercial opportunities in sizeable underserved markets.
The company is also developing an integrated health platform that combines its pharmaceutical portfolio with digital education, patient engagement and prescribing pathways. Through its women’s health and men’s health information platforms, ReclaimMyCycle.com and StiffIssue.com, EVE seeks to improve awareness, reduce stigma and encourage earlier access to care. These platforms connect with telehealth and pharmacy fulfilment networks to support scalable treatment access within a regulated healthcare setting.